心房颤动患者发生出血性卒中或创伤性颅内出血后重启华法林治疗的相关结局
这项全国性观察性队列研究纳入1998年1月1日至2016年2月28日期间在华法林治疗中发生首次颅内出血事件的房颤患者2415例(男性1481例[61.3%],女性934例[38.7%],平均[SD]年龄77.1[9.1]岁),其中出血性卒中1325例、创伤性颅内出血1090例,随访至2016年4月30日。出院后重启华法林作为时间依赖性暴露,采用时间依赖性Cox比例风险回归模型校正年龄、性别、住院时长、合并症及合并用药。出血性卒中组重启华法林与未重启相比,缺血性卒中或系统性栓塞调整风险比0.49(95%CI 0.24-1.02)、复发性颅内出血调整风险比1.31(95%CI 0.68-2.50),均未达统计学显著;创伤性颅内出血组重启华法林与缺血性卒中或系统性栓塞调整风险比0.40(95%CI 0.15-1.11)、复发性颅内出血调整风险比0.45(95%CI 0.26-0.76,显著降低)。重启华法林与出血性卒中组死亡率降低相关(调整风险比0.51,95%CI 0.37-0.71),也与创伤性颅内出血组死亡率降低相关(调整风险比0.35,95%CI 0.23-0.52)。
要点
- 房颤患者华法林相关颅内出血后重启华法林,出血性卒中组死亡率调整风险比0.51(95%CI 0.37-0.71),创伤性颅内出血组0.35(95%CI 0.23-0.52)。
- 创伤性颅内出血后重启华法林,复发性颅内出血调整风险比0.45(95%CI 0.26-0.76),显著低于未重启者。
- 出血性卒中后重启华法林,复发性颅内出血调整风险比1.31(95%CI 0.68-2.50),未达统计学显著。
- 出血性卒中后重启华法林,缺血性卒中或系统性栓塞调整风险比0.49(95%CI 0.24-1.02),未达统计学显著。
- 创伤性颅内出血后重启华法林,缺血性卒中或系统性栓塞调整风险比0.40(95%CI 0.15-1.11),未达统计学显著。
适用人群与场景
- 1998年1月1日至2016年2月28日期间在华法林治疗中发生首次颅内出血事件的房颤患者,来自全国性观察性队列。
- 共2415例,其中出血性卒中1325例、创伤性颅内出血1090例;男性1481例(61.3%),女性934例(38.7%);平均(SD)年龄77.1(9.1)岁。
- 出院后评估是否重启华法林治疗;随访至2016年4月30日。
研究设计与关键结果
- 研究类型:全国性观察性队列研究;样本量2415例房颤患者(出血性卒中1325例、创伤性颅内出血1090例)。
- 暴露:出院后未接受口服抗凝治疗或重启华法林治疗,作为时间依赖性暴露;采用时间依赖性Cox比例风险回归模型,校正年龄、性别、住院时长、合并症及合并用药。
- 主要结局:出血性卒中组重启华法林 vs 未重启,缺血性卒中或系统性栓塞调整风险比0.49(95%CI 0.24-1.02),复发性颅内出血调整风险比1.31(95%CI 0.68-2.50),均未达统计学显著。
- 创伤性颅内出血组重启华法林 vs 未重启,缺血性卒中或系统性栓塞调整风险比0.40(95%CI 0.15-1.11),未达统计学显著;复发性颅内出血调整风险比0.45(95%CI 0.26-0.76),显著降低。
- 死亡率:出血性卒中组第一年305例(23.0%)死亡,创伤性颅内出血组210例(19.3%)死亡;重启华法林与出血性卒中组死亡率降低相关(调整风险比0.51,95%CI 0.37-0.71),也与创伤性颅内出血组死亡率降低相关(调整风险比0.35,95%CI 0.23-0.52)。
证据类型、等级与局限
- 证据类型:全国性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于华法林治疗中发生颅内出血的房颤患者,出院后是否重启华法林需权衡缺血与再出血风险;本观察性研究显示重启华法林与出血性卒中及创伤性颅内出血患者死亡率降低相关。
- 创伤性颅内出血患者重启华法林与复发性颅内出血率显著降低相关(调整风险比0.45,95%CI 0.26-0.76),而出血性卒中患者重启华法林与复发性颅内出血率无显著差异(调整风险比1.31,95%CI 0.68-2.50)。
- 出血性卒中患者重启华法林与缺血性卒中或系统性栓塞率无显著差异(调整风险比0.49,95%CI 0.24-1.02),创伤性颅内出血患者同样无显著差异(调整风险比0.40,95%CI 0.15-1.11)。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The increase in the risk for bleeding associated with antithrombotic therapy causes a dilemma in patients with atrial fibrillation (AF) who sustain an intracranial hemorrhage (ICH). A thrombotic risk is present; however, a risk for serious harm associated with resumption of anticoagulation therapy also exists.
OBJECTIVE: To investigate the prognosis associated with resuming warfarin treatment stratified by the type of ICH (hemorrhagic stroke or traumatic ICH).
DESIGN, SETTING, AND PARTICIPANTS: This nationwide observational cohort study included patients with AF who sustained an incident ICH event during warfarin treatment from January 1, 1998, through February 28, 2016. Follow-up was completed April 30, 2016. Resumption of warfarin treatment was evaluated after hospital discharge.
EXPOSURES: No oral anticoagulant treatment or resumption of warfarin treatment, included as a time-dependent exposure.
MAIN OUTCOMES AND MEASURES: One-year observed event rates per 100 person-years were calculated, and treatment strategies were compared using time-dependent Cox proportional hazards regression models with adjustment for age, sex, length of hospital stay, comorbidities, and concomitant medication use.
RESULTS: A total of 2415 patients with AF in this cohort (1481 men [61.3%] and 934 women [38.7%]; mean [SD] age, 77.1 years [9.1 years]) sustained an ICH event. Of these events, 1325 were attributable to hemorrhagic stroke and 1090 were secondary to trauma. During the first year, 305 patients with a hemorrhagic stroke (23.0%) died, whereas 210 in the traumatic ICH group (19.3%) died. Among patients with hemorrhagic stroke, resuming warfarin therapy was associated with a lower rate of ischemic stroke or systemic embolism (SE) (adjusted hazard ratio [AHR], 0.49; 95% CI, 0.24-1.02) and an increased rate of recurrent ICH (AHR, 1.31; 95% CI, 0.68-2.50) compared with not resuming warfarin therapy, but these differences did not reach statistical significance. For patients with traumatic ICH, resuming warfarin therapy also was associated with a lower rate of ischemic stroke or SE (AHR, 0.40; 95% CI, 0.15-1.11); however, in contrast to patients with hemorrhagic stroke, therapy resumption was associated with a significantly lower rate of recurrent ICH (AHR, 0.45; 95% CI, 0.26-0.76). A reduction in mortality was associated with resuming warfarin therapy among patients with hemorrhagic stroke (AHR, 0.51; 95% CI, 0.37-0.71) and those with traumatic ICH (AHR, 0.35; 95% CI, 0.23-0.52).
CONCLUSIONS AND RELEVANCE: Resumption of warfarin therapy after spontaneous hemorrhagic stroke in patients with AF was associated with a lower rate of ischemic events and a higher rate of recurrent ICH. Among patients with a traumatic ICH, a similar lower rate of ischemic events was found; however, a lower relative risk for recurrent ICH despite resuming warfarin treatment was also revealed.
参考来源
- Nielsen PB, Larsen TB, Skjøth F, et al. Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. JAMA Intern Med. 2017. PMID: 28241151. doi:10.1001/jamainternmed.2016.9369
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。